RET and medullary thyroid gland carcinoma: In a small phase II trial (LIBRETTO-321) in a Chinese population with RET-mutant MTC and RET fusion-positive DTC, the objective ORR was found to be 57.7% (95%CI, 36.9–76.6) [53].